Hemoglobin Variant, A2 and F Quantitation, Blood
Use
This test is primarily used for monitoring patients with sickling disorders who have undergone therapy with hydroxyurea or transfusion. It is intended to track increases in fetal hemoglobin (HbF) levels after therapy and the percentage of hemoglobin S (HbS) after transfusion, providing crucial data to guide further treatment plans.
Special Instructions
This test is not intended for diagnostic or screening purposes. If diagnostic evaluation is needed, hemoglobin electrophoresis should be used (see HBEL1 / Hemoglobin Electrophoresis Evaluation, Blood). It's essential to submit a fresh whole blood specimen in its original tube without aliquoting.
Limitations
The test, performed via capillary electrophoresis, reports percentages of hemoglobin variants, but it is not confirmatory for specific variants and cannot be used for screening due to low sensitivity for uncommon variants. Peaks in certain zones may not represent specific hemoglobin fractions, and therapy artifacts may impact results. Variants may originate from transfused blood rather than the patient.
New York Approved
Methodology
Automated Analyzer (Clinical Chemistry)
Biomarkers
LOINC Codes
- 43113-0
- 20572-4
- 32682-7
- 4552-6
- 24469-9
- 78748-1
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
4 mL
Minimum Volume
1 mL
Container
Lavender top (EDTA) or Yellow top (ACD)
Collection Instructions
Submit fresh specimen. Send whole blood specimen in original tube. Do not aliquot.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 10 days |